• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Simmons Cancer Center - Developmental Therapeutics Review - Q1 2011 Product Image

Simmons Cancer Center - Developmental Therapeutics Review - Q1 2011

  • Published: March 2011
  • 60 pages
  • Global Markets Direct

Simmons Cancer Center – Developmental Therapeutics Review – Q1 2011

Summary

Global Market Direct’s pharmaceuticals report, “Simmons Cancer Center – Developmental Therapeutics Review – Q1 2011” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.

Scope

- Review of therapeutics under development by Simmons Cancer Center.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Simmons Cancer Center with complete description READ MORE >



List of Tables
List of Figures
Simmons Cancer Center Snapshot
Simmons Cancer Center Overview
Key Information
Key Facts
Simmons Cancer Center – Research and Development Overview
Key Therapeutic Areas
Simmons Cancer Center – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Simmons Cancer Center – Pipeline Products Glance
Simmons Cancer Center – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Simmons Cancer Center Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Phase I Products/Combination Treatment Modalities
Simmons Cancer Center – Drug Profiles
Pregabalin
Product Description
Mechanism of Action
R&D Progress
Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Autologous Immunoglobulin Idiotype-KLH Conjugate Vaccine + Methotrexate + Thiotepa + Sargramostim + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Autologous immunoglobulin idiotype-KLH conjugate vaccine + Sargramostim + Methotrexate + Thiotepa
Product Description
Mechanism of Action
R&D Progress
carboplatin + doxorubicin hydrochloride
Product Description
Mechanism of Action
R&D Progress
carboplatin + paclitaxel + sorafenib tosylate + radiation therapy
Product Description
Mechanism of Action
R&D Progress
carboplatin + paclitaxel + vandetanib + radiation therapy
Product Description
Mechanism of Action
R&D Progress
cetuximab + cisplatin + radiation therapy
Product Description
Mechanism of Action
R&D Progress
Doxorubicin + Carboplatin
Product Description
Mechanism of Action
R&D Progress
Fludarabine + Allogeneic Stem Cell Transplantation + Donor Leukocyte Infusion + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
fludarabine + stem cell transplantation + radiation theraphy
Product Description
Mechanism of Action
R&D Progress
IMTOX25
Product Description
Mechanism of Action
R&D Progress
ixabepilone
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Carboplatin + Vandetanib
Product Description
Mechanism of Action
R&D Progress
paclitaxel + cisplatin + cetuximab + radiation therapy
Product Description
Mechanism of Action
R&D Progress
paclitaxel + sorafenib tosylate
Product Description
Mechanism of Action
R&D Progress
Tamoxifen
Product Description
Mechanism of Action
R&D Progress
Tarceva + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
therapeutic allogeneic lymphocytes + cyclophosphamide + cyclosporine + fludarabine + methotrexate + mycophenolate mofetil + tacrolimus + radiation therapy + stem cell transplantation
Product Description
Mechanism of Action
R&D Progress
Ad5CMV-p53 Gene Therapy
Product Description
Mechanism of Action
R&D Progress
Gemcitabine Hydrochloride + Radiation Therapy
Product Description
Mechanism of Action
R&D Progress
Paclitaxel + Radiotherapy
Product Description
Mechanism of Action
R&D Progress
Pioglitazone
Product Description
Mechanism of Action
R&D Progress
pioglitazone hydrochloride
Product Description
Mechanism of Action
R&D Progress
Simmons Cancer Center – Pipeline Analysis
Simmons Cancer Center – Pipeline Products by Therapeutic Class
Simmons Cancer Center - Pipeline Products By Target
Simmons Cancer Center – Pipeline Products by Route of Administration
Simmons Cancer Center – Pipeline Products by Molecule Type
Simmons Cancer Center – Locations And Subsidiaries
Head Office
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos